One Nucleus Annual Review 2022 - Q4 Update

Annual Review 2022 - Q4 UPDATE

Sponsored by

Process Chemistry & Analytical

DMPK Webinar Series CGT Webinar Series Chemistry Lecture Series

A Warm Welcome from Tony Jones

This yearly publication provides the opportunity for us to reflect on a year of One Nucleus activities, to highlight some of the successes and gained insights among our members and the wider Life Sciences sector. Further, it is also a chance to share with our network some thoughts and plans we have for the year ahead with regards to our focus and how we aim to offer the best support to the membership.

I am delighted this year that we have included more details of the activities delivered in 2021 since these are not a simple reflection of what the One Nucleus team has been doing but also illustrates well what our network has engaged in as it continues to adapt to a world coming out of the pandemic.

Learning Lessons from Challenges

Business practices changed for all when it came to deal making, workplace operations and everyone’s daily life as we encountered the pandemic. The uncertainty remains in some respects of course and it seems inevitable that after such a disruption, things will not just return to the pre-Covid business-as-usual operations. Lessons are always learned from challenges, we must hope to retain some of the efficiencies that were introduced.

It was exciting to hear at numerous One Nucleus events and other meetings how the sector’s thought leaders have adopted new ways of working with the intention of accelerating the translation of great innovation into a more integrated patient benefit.

Highlights in this Review

Within this review you will get the opportunity to read some contributed editorial articles from PharmaVentures, BioMed Realty and Mills & Reeve along with learning about the highlights from our own One Nucleus work. This will include a recap of our conferences (Building Life Science Adventures, ON Helix and Genesis) as well as click throughs if you’d like to catch a recording of sessions you missed or would like to see again. This latter option a benefit of it having been necessary to turn to virtual events. This recording option for on-demand catch-up is an offer we have retained whilst returning to in-person events on a regular basis.

The review of One Nucleus activities will continue as you read, to provide updates on our Virtual Innovation Centre, Training Courses that sixty companies have utilised, the launch of our ‘Employer of Choice’ and Mentoring scheme after topics aired at BLSA 2021, the forty-nine nonconference events, the Member Savings performance and how we have advised on a record level of R&D Space design and fit-out to name but some. Not just a listing of the One Nucleus membership offer, but the data that illustrates how we deliver.

Sector Resilience and Activity

2021 was another record-breaking year when it came to investment attracted by the Life Sciences industry. By way of example, $7.3Bn was invested globally in just Jun-Aug 2021, led by the US at $4.37Bn. The UK continued to lead in Europe at $429M in that period whilst over the year as a whole the UK Life Sciences sector raised £4.5Bn, a staggering £1.7Bn more than in 2020 (cf Clarivate & BIA). One Nucleus members including Artios Pharma, Microbiotica, Healx and Nuclera Nucleics are just some of those who raised significant rounds. It’s not just about venturebacked companies either.

Our Corporate Patron, AstraZeneca is predicted to generate the biggest new sales in 2022 estimated at $7.0Bn (Evaluate Vantage). The excellence in translational research within our membership is magnetic to others wanting to locate or work with the region with not just the primary bio-venture investment that powers the growth here.

The ability to attract scientific talent, the growing pool of experienced innovative business leaders, strong networks and global connectivity means the entire ecosystem attracts a meaningful portion of revenue flows from within the industry. The impressive growth of R&D partners such as Domainex, Abzena and Phoremost, who are leveraging their proprietary platforms to attract deals whilst developing their own asset pipelines, is illustrated by them all expanding into larger facilities recently as their client base has grown.

How We Support the Network

Taking the feedback from our members on board as we continue to evolve the One Nucleus value proposition, we seek the best ways to:

• Support innovation and those organisations and leaders driving translation of their innovation towards new healthcare interventions to improve patient outcomes.

• Enable the connectivity of all stakeholders, each bringing their unique combination of expertise, resource and dynamism to the sector and seeking to collaborate.

• Promote the career opportunities the Life Science industry offers, whether those careers are at the bench, in business or within the wider ecosystem.

• Inform our members of the latest developments and trends across all topics including reference to operational roles such as HR, Marketing and Purchasing through our thematic group sessions.

• Enable access to the optimal meeting opportunities, whether in-person or online and whether these are forums delivered directly by One Nucleus, in collaboration with others or at discounted rates to commercial events such as BioEurope, Biotech Integrates and BioTrinity.

• Promote good practice in the area of being a good employer and corporate citizen. Adopting better practices ourselves where possible and importantly showcasing the good practice to our network and encouraging wider adoption.

Focus is Key

By way of completing this welcome section, I include here the framework of focus areas the One Nucleus team has developed to help guide our various activities and performance for our stakeholders.

INNOVATION SUPPORT STAKEHOLDER ENGAGEMENT

• Virtual Innovation Centre (VIC)

• Knowledge Exchange

• Member Savings

• Learning & Development

• Recruitment & Retention

• Facilities Support

• Profile & Promotion

• Government Support Opportunities

• Sponsors & Members

• The Life Science Sector

• Policy Influencers

• Collaborators

• Patients

EVENTS BUSINESS PRACTICE

• Conference Portfolio - (ON Helix, Genesis,

• Building Life Science Adventures)

• Innovation Seminars/Round Tables

• BioWednesdays

• Peer-to-Peer Networking Events

• Collaborative Events

Looking Ahead

• Improving Business Resilience

• Being an Employer-of-Choice

• Sustainability in Action

• Supporting Diversity

• Community Engagement

I, or indeed any member of the One Nucleus team detailed in what follows, stand ready and willing to discuss any of the work we do and opportunities engaging with One Nucleus can present. I hope you enjoy the various articles, updates and window on our forward-looking plans contained in this 2022 Annual Review. I very much look forward to meeting again soon and supporting you on your journey to success.

Best wishes, Tony Jones, CEO

Innovation Support

If starting-up a life science company is hard, growing that company comes with the exponential challenges of becoming increasingly operational as well as active dealmakers.

It is from this observation and based on the One Nucleus strengths and connectivity that the Virtual Innovation Centre concept emerged in 2021 as a supporting tool for Life Science companies on their growing journey.

Analyses – like this very interesting article from McKinsey – often point to the translation of science and innovation into commercialisation as the weak point in European Life Sciences. Many causes keep being identified, such as the smaller size of initial funding rounds, lack of managerial expertise, or company culture, but none of those factors are terminal and this is where the power of a network can be leveraged.

The One Nucleus Virtual Innovation Centre is working on four key areas to support growing Life Science companies. Detailed here is what is being delivered, and how, in terms of support:

Preparation and access to capital

Raising money is an on-going task for Life Science entrepreneurs but the role evolves as the company grows, along with the type of investor and their expectations and demographic.

The VIC delivered sessions supported by its partners Oyster Venture Partners and Taylor Wessing on the topics of Transactions for Growth and Best Practices to De-risk your Fundraising covering how to best prepare for different deals and investment types. These sessions are complemented by the One Nucleus investors’ network which is very active in the ecosystem.

Developing deal making activities

Companies’ development journeys will converge with deal making, whether in the form of research collaboration or contract research and outsourcing with suppliers or clients. This element contains a need to build commercial connection. The VIC has helped companies like Leaf Expression System and Eagle Genomics by involving them in One Nucleus’ flagship conferences ON Helix and Genesis. It also requires technical knowledge, that our partners Penningtons Manches Cooper, Fish & Richardson and pharma partners such as Lilly provide, with sessions such as Anatomy of a Research Collaboration Agreement

Enhancing R&D capacities and outsourcing

Fundraising and deals only happen when companies generate enough innovation. This obvious statement means that the capacity to grow R&D capacity and plan later stage development is essential to companies’ success.

The VIC is fortunate to include a breadth of development partners including Catalent, Charles River, Lonza, Thermo Fisher and tranScrip who shared their expertise in sessions such as Growing Lab Capacity including Outsourcing, Purchasing and Digitally Native lab, and the session Growing with Underlying Principles of Drug Development.

Innovation Support

Strengthening business operations.

This element is rarely at the forefront of companies’ priorities, however it is as essential as the R&D operation in growing a business successfully.

This is why supporting this part is crucial, so entrepreneurs can concentrate on delivering good science and the strategic developments.

Our executive recruitment experts George James and law firm Penningtons Manches Cooper offered advice and shared their expertise during sessions on the topics of Identifying and Filling Gaps in the C-suite and Board and Growing with Confidence in Employees

We had good engagement with the following companies over the year who benefitted from the sessions, contacts and opportunities offered within the One Nucleus conferences.

Biorelate, Broken String Biosciences, Carocell Bio, Colorifix, Curileum Discovery, Drishti Discovery, Eagle Genomics, ET-traps, Kantify, Leaf Expression Systems, Mestag Therapeutics, Monument Therapeutics, MultiplAI Health, Nuclera Nucleics, Pharmenable, Semarion, Talisman Therapeutics, Valirx.

We’re looking forward to continuing to support them and others who would like to join us on their journey.

For more information, please contact info@onenucleus.com.

• 12 month tailored seminar programme.

• 1-2-1 meetings with leading experts.

• Profile at One Nucleus and external conferences.

• Directed 1-2-1 introductions.

• International connectivity.

• Gold membership benefits.

Learning and Development

Focus and news flow is often on highlighting world leading technology breakthroughs and impressive investment rounds and deals in the Life Sciences sector as life-changing products are invented and translated to improved patient care. It is vital not to forget the third pillar that supports the enviable track record. Inventions, collaborations, deals and therefore impact requires people.

One Nucleus supports members, individuals and the wider sector through a suite of interventions targeted to meet the aspirations of our members which can be summarised as follows:

Attract the best talent and skills. Motivate their employees. Engender loyalty. Operate an open and safe environment. Harness the strengths of diversity. Enable personal development of their staff. Encourage innovation at all levels. Deliver fair reward for performance.

Be a good corporate citizen delivering value for all stakeholders. Offer flexibility to meet business and employee needs in an equitable manner.

Learning & Development:

Business leaders frequently confirm that their company’s employees are its most valuable assets. A mantra that has never been more relevant than now when competition for the best people has never been more intense. Retention and development of staff is as key to successful growth as effective recruitment. We have developed a range of Learning and Development support opportunities including:

• A broad Training Course portfolio, delivered face-to-face or online to meet member companies’ needs.

• Training Courses can be delivered in-house for a single company or open courses as required.

• Members receive up to 30% discount on Training Courses when booking.

• Free on-demand content from our events and conferences to fill knowledge gaps within teams.

Recruitment & Retention:

• Website listing of job vacancies.

• Focussed ‘Employer of Choice’ sessions to discuss best practice.

• Thematic forums in Skills and HR.

• Annual Building Life Science Adventures conference.

People Pathways Newsletter:

• Monthly e-publication disseminated to our network.

• Learning & Development insight articles.

• Recent appointments at member companies.

• Current vacancies.

• Up-coming Training Courses. For more information, please email our One Nucleus Learning and Development team

Learning and Development in Review

During the past 12 months we have been encouraged to see a continued uptake in training courses with both open and in-house delivery amongst member companies. Through feedback we know that whilst the development of staff is important, retention of those staff is certainly key in an increasingly competitive recruitment market.

In 2021, 60 companies booked onto an even spread of compliance and essential skills courses, delivered both online and in-person, and we saw an increase in the number of member and nonmember in-house courses delivered.

Employer of Choice

The growth in competition to secure and retain the best employees, the changing career and working flexibility aspirations of those employees and the desire of our leaders to align with societal changes with regards to Equality, Sustainability and Governance (ESG), in 2021 saw the launch of our Employer of Choice webinar sessions. These sessions covered topics as wide ranging as women’s health and safety at work; reducing carbon footprint; LGBTQ+ inclusion; working with neurodiversity and more. The common thread being to engage employers in how to build their best Employee Value Proposition.

Watch the Employer of Choice Sessions here

We welcomed 96 attendees joining sessions on:

• Wellbeing – Helping Employees Stay in Tune

• Women’s Safety in the Workplace

• Women’s Health and Wellbeing in the Workplace

• Reducing Carbon Footprint

• Creating a Diverse and Inclusive Workplace

This year saw 194 attendees and 50 speakers participate.

The topics covered:

• How do You Build People Skills? • How Much Should You Value Experience Over Qualifications? • Reinventing Recruitment Post-Covid and Diversity and InclusionProgressing from Intention to Practice • How Will AI Change Life Science Careers? • Is Being an Entrepreneur a Career? • Do Role Models Make Great Mentors? • Fishing in a Global Pond • BioWednesday Webinar: What is the Best Use of Carbon in the Life Science Sector?

Watch the sessions here

Looking forward to next year’s BLSA - SAVE THE DATE - 28–29 March 2023!

NEW! One Nucleus Mentoring Initiative

The One Nucleus Mentoring Initiative was created in summer 2021, with several of the panels at Building Life Science Adventures 2021 having highlighted its importance. Being surrounded by and learning from great people was deemed important in all stages of a career.

We are here to help find a mentor - it’s our chance to play our full role in connecting the expertise and know-how of our network to those that need it and thereby collectively enhancing the success of the cluster.

Contact training@onenucleus.com with details about what you currently do, the type of mentor you seek and the area of expertise on which you seek their guidance. Free of charge, we’ll advertise your mentor vacancy on our LinkedIn, Twitter, website and monthly People Pathways newsletter.

The image above is an example of what the advert could look like. We will keep you updated and connect you to those who get in touch. Since launching, mentors have supported and guided mentees through key business decisions, new careers, internship/placement advice and more. We collaborated with the Society for Laboratory Automation and Screening (SLAS) to enhance the mentee experience. Those that signed up for the SLAS Mentor Match programme received access to a complimentary 6-month membership with SLAS.

Recruitment & Retention - Our job vacancies page has been extended to non-members for a fee, and we set up a Linkedin Group for HR opportunities. We continued to offer our range of themed webinars on Skills and HR.

People Pathways Newsletter

People Pathways is a monthly e-publication disseminated to our network, covering Learning & Development insight articles, recent appointments at member companies, current vacancies and upcoming Training Courses.

For more information, please email our One Nucleus Learning and Development team

Events

Events are an essential part of the One Nucleus offer. In addition to our flagship conferences, we deliver a range of events where members and non-members showcase their expertise and enable knowledge exchange, debate and networking between members and non-members.

The main categories of our events are illustrated below alongside the numbers delivered for each throughout the past year:

Innovation Seminars – Includes full day/half day/breakfast sessions on technical topics including solutions to challenges in R&D as well as law, IP and finance topics. This series includes sessions that are part of the One Nucleus Virtual Innovation Centre programme to support early-stage companies as they become increasingly operational.

Thematic Groups – Focused sessions covering updates and best practice discussions on HR, Marketing and People related topics.

BioWednesdays – Monthly member benefit events that bring our network together over key topics and networking.

Networking Mixers – A chance to network and connect with the One Nucleus Life Science community in a less formal environment such as social venues and over dinner.

Whether you are looking to attract your next collaborator, client or investor, our events are an excellent opportunity to help you make new connections and to fill knowledge gaps to help facilitate your growth. They are open to members and non-members with members gaining free and discounted access to some, while others are open and free to all. As the chart below illustrates, we have a good representation of both members and non-members at our events, reflecting the wider audience that they attract.

We look to our members first for speaking opportunities and over the past year have recruited >100 speakers for our events. We also have sponsorship opportunities available for those looking to raise their profile with this key network. In the past year, One Nucleus has been proud to work with sponsors including:

EVENT SPONSORS

Our events cover a wide breadth of topics that are relevant to the local Life Science community, highlighting the region’s strengths and also reflecting the evolution of the sector including technology trends. Some will also leave delegates with practical tips to take away! Below are some stand out topics from the past year to highlight what our network has been talking about.

BioWednesday Webinar: Enabling AI in Drug Discovery - A session in collaboration with Stevenage BioScience Catalyst that discussed how AI is impacting drug discovery and beyond, and how companies can mature innovation in this space in terms of which business model to use, accessing and raising investment and recruiting skilled staff. The recording of this session can be accessed here.

BioWednesday Webinar: Opportunities for UK Life Sciences - A US Perspective - A session in collaboration with Fish & Richardson that discussed the strengths and weaknesses of the UK’s position in global biotech and what this means for UK companies seeking investment, deals and alliances in the US. The recording of this session can be accessed here.

Advanced Biobanking: Learn from IBX How to Harness the Potential of Biobanks - A member webinar sponsored by Infinity BiologiX that shone a light on the importance of biobanking and sharing high quality data to ensure the future success of genomic and regenerative medicine. The recording of this session can be accessed here.

Networking Mixer at Queen Mary Enterprise Zone - An opportunity for members and nonmembers to connect. This event featured a speaker from the Digital Environment Research Institute (DERI) and Deep Science Ventures to help set the scene for the networking that followed.

Life Science Marketing Group: The Transition from Virtual to Hybrid and Live Events for the Life Sciences Sector - In collaboration with Giggabox and a hot topic for many in the industry following the pandemic which saw the world of virtual and live events merge. The recording of this session can be accessed here.

This one-day conference addresses the main bio innovation trends, from the developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments.

Don’t miss this annual opportunity to reconnect with the One Nucleus network and keep up to date with the latest trends in Bio Innovation for Health.

ON Helix offers • a high content mix of plenary talks and panels from key opinion leaders

• networking with 250+ delegates • 1-to-1 virtual meetings with in-person and digital only delegates

• ON Helix Fringe events including digital Innovation Workshops • an ‘Innovation Engine Room’ showcasing the most innovative early-stage life science companies and innovation supporters from the network.

Genesis assembles senior executives and decision-makers from across the Life Science, Healthcare and Technology field to present, discuss and demonstrate their collective insight and thought leadership for the sector, themselves and their stakeholders.

Genesis offers: • a high content mix of plenary talks and panels from key opinion leaders • Innovation Workshops for further technical and business insights • Face to face networking and digital 1-2-1 meetings with delegates from across the international Life Science and Healthcare industry • popular Fringe Events.

Creating careers not just jobs is a two-way process between those seeking to build their adventures in science and those seeking to employ them with academia a critical enabler. This two-day free to attend digital careers conference is a chance to fill knowledge gaps, debate best practice and connect to enable success. Not your standard job fair, this is an event bringing panels of students, early career seekers, employers and universities together to engage in lively discussions over the course of two days.

ON Helix and Genesis in 2021 – Reconnecting the ecosystem

After a full year of digital conferences, 2021 highlighted a need for reconnection, albeit remaining digital for ON Helix in July with 400+ delegates but excitingly in-person for Genesis in December where more than 200 delegates enjoyed connecting with peers.

Although ON Helix and Genesis have a slightly different foci and therefore audiences, they share the same purpose; conferences designed with and for the One Nucleus network.

Beyond the exciting connection opportunities, it means that discussion topics are those our network want to engage with and can contribute to. Here is a look at the key highlights:

ON Helix 2021 – New Medicines in a Brave New World

Following 2020 and the way the life science community combined resources, ingenuity and hard work to deliver prophylactic and therapeutic tools against the pandemic, ON Helix addressed the lessons learnt on how translation of science into developing new therapeutics and healthcare technologies can be improved and in addition, how to collectively build this ‘Brave New World’.

The one and a half days of live sessions covered some of the key technology trends such as mRNA technologies, innovations in drug discovery and the diagnostics revolution as well as the wider environment making them possible, including talents, research funding and ecosystems.

ON Helix 2021 also highlighted the drive to greater sustainability with a keynote introduction from Penny James, COO R&D Biopharmaceuticals at AstraZeneca, articulating the efforts the industry was making in this domain and AstraZeneca in particular. For the first time the agenda included non-medical life science companies to discuss their own contribution to health by developing more sustainable processes (Colorifix, Leaf Expression Systems) or alternatives to animal products (Higher Steaks).

As this event was still digital, it was also packed with really exciting on-demand content including the Biotech Rising Star pitches presenting the next generation of biotechs; a series of discussions on ecosystems as enablers for talent, digitalisation or entrepreneurship; and fireside chats with top level industry representatives including Francesco de Rubertis, Centessa Founder and Claire Skentelbery, Director General, EuropaBio and many more!

Because we like to share these insights with our network, the full ON Helix 2021 playlist is available on the One Nucleus YouTube channel.

Keynote Speaker: Penny James, AstraZeneca

Delegates engaged with ON Helix via an app

Genesis 2021 – Celebrating our 21st anniversary in style

Genesis is our annual end of year conference bringing together the One Nucleus network of key industry leaders to reflect on the past year’s most significant trends in innovation as well as macro trends such as deals, investment and corporate considerations.

As 2021 was another exciting year for the life science sector, there were many insightful and thought-provoking discussions covering:

• Money and the enormous influx of cash we have seen translated in an impressive level of deal activity. It brought a lot of optimism about how resources and interest gained by our industry could have significant impact on reducing the time it takes to bring innovation to patients.

• Drugs and the lessons learnt to accelerate the development of new medicines brought on by Covid vaccine success stories.

• Patients, that we were reminded we all are, and the importance of patient centricity at the earliest stages.

• Technology, especially the adoption of genomics to improve healthcare delivery.

• Innovation, and how to learn from other sectors like automotive, engineering, retail and performing arts. Sessions are available on the One Nucleus YouTube channel.

The Events’ Innovation Workshops – Sharing Expertise

Both ON Helix and Genesis leveraged the benefits of having a digital component with one hour Innovation Workshops around the conference. The Innovation Workshops, led by experts from the One Nucleus network delivered educational sessions on business, operations and technology topics with insights into international ecosystems.

The full list of topics covered in 2021 is below and all sessions are available to watch on-demand. International

• Alternative Listing Venues - Have You Thought About Asia?

• Accelerating Market Access for Digital Health Innovation between Québec and UK

• Learn about the Latest Japanese Startup Ecosystem

• Hong Kong Biomedical Cluster and Leading IPO Center in Asia

Drug Discovery

• Data Inspired Medicines Design

• Then and Now – Delivering a Successful Therapeutic to Patients

• Demonstration of CDD Vault for Accelerating Drug Discovery

Drug Development

• Improving Patient Outcome with Better Clinical Data Interoperability

• Data Protection in Clinical Trials

Regulatory

• Supporting Innovation Through Regulatory Interactions

• How Regulatory Compliance in Medtech Is a Tool for Success

• AI in the medical industry – Artificial Hope or Intelligent Solutions?

• MedTech and the Internet of Medical Things

Business

• Navigating Patent Protection and Freedom to Operate for Antibody Technologies

• Getting Investment or Deal Ready- How to Prepare for IP Due Diligence

• How Does Real Estate Facilitate the Growth of the Life Sciences Sector?

• Solving Scientific Talent Gaps: Stories Behind the Attraction & Retention

MedTech

• Five Trends Reshaping the Future of MedTech

• The Impact of the Covid Pandemic on Healthcare Innovation

Meet the Team

Richard Dickinson Chief Technical Specialist

Jean Chief Operating Officer

Claire Abrams Director of Events & Communications

Alicia Gailliez Business Development Manager

Debbie Flicos Finance & Systems Administrator

Natalie Keuroghlian Marketing Manager

Jasmin Bannister Events & Communications Administrator

Tony Jones Chief Executive Officer

Laura Bacchus Events & Data Administrator

Andrew Bickerton CRM Manager

Corporate Patron

Corporate Sponsors

Our Corporate Patron

One Nucleus is delighted that AstraZeneca will continue its long-held relationship as Corporate Patron. For over a decade AstraZeneca has provided significant strategic advice from employees in a variety of departments and roles to help steer our activities. Highlighting AstraZeneca’s commitment to the partnership with One Nucleus, it is our pleasure to have Penny James, Chief Operating Officer, BioPharmaceuticals R&D as a NonExecutive Director. The breadth of this engagement means we have formed a strong and productive relationship with AstraZeneca, based on shared ambitions for the Cambridge and wider UK life sciences community.

Accommodating over 2,200 research scientists nothing illustrates AstraZeneca’s commitment to the region’s life science cluster more clearly that its investment in establishing their new Discovery Centre (DISC). Opened by HRH Prince of Wales in late 2021 the prestigious facility epitomises the future of life science R&D; technologyenabled, collaborative and patient-centric. One Nucleus shares this ambition for the cluster to be the world-leading bioinnovator. One Nucleus strives to enable knowledge sharing on the latest innovations in the scientific, business and investment aspects of the sector. AstraZeneca’s willingness to dedicate resource to us, such as event speakers and updates, significantly enhances our ability to share and debate content across areas including R&D, deal making and sustainability. Their engagement provides insight to the nascent companies, their founding entrepreneurs and investors, on how exceptional scientific innovation can be translated into patient benefit globally.

This fits well with the collective aspirations of our cluster’s ecosystem; to create life changing technologies and products that have a global impact on lives. AstraZeneca’s role as a global leader and regional champion, in terms of science and societal impact includes their local engagement in mentoring-style schemes and strong practices on environment and diversity, exemplifying the aspirations of the cluster and One Nucleus’s desire to promote the region as the best place for life science talent to work, live and collaborate.

Tony Jones, CEO

One Nucleus Partners

Partner Programme

The One Nucleus Partner Programme offers a fully integrated value proposition to organisations seeking to play an influential and visible role in the development of the One Nucleus life science community.

Relationship Management:

Each Partner has a tailored Annual Engagement Plan, developed to ensure a good strategic fit with the Partner’s goals for the year ahead and against which performance can be managed. There is an allocated One Nucleus account manager for each relationship to ensure regular reviews and discuss desired adjustments as the year progresses. Engagement may include benefits from the menu below, but the agreed package is designed with flexibility in mind.

Partner Benefits:

• One Nucleus Gold Membership.

• Company logo displayed with advised url hyperlink on the One Nucleus website

• Company logo and url hyperlink in the One Nucleus Annual Review.

• Opportunity to speak at One Nucleus events (based on relevance and experience).

• Contribution of thought leadership articles to One Nucleus publications.

• Placement of a banner advertisement and article in an edition of One Nucleus eNews.

• Option to develop bespoke event(s) or workshop(s) to be delivered with One Nucleus.

• Three digital delegate passes to any One Nucleus conference offering such an option.

• One in-person delegate pass to any One Nucleus conference offering such an option.

• Annual 1-2-1 meeting with the CEO of One Nucleus to discuss issues facing the life science sector and possible One Nucleus interventions.

• Priority invitation to any VIP-only events hosted by One Nucleus.

* To become a One Nucleus Partner the cost is £8,390 +VAT per annum

For information: +44(0)1223 896450 info@onenucleus.com www.onenucleus.com

GROW SCALE FORM

BIRMINGHAM

Did You Know as a Member You Can...?

Connect via groups in the EU, North America, Australasia & Asia

Save more than your membership fee via member discounts

Post job vacancies online Access the on-demand library of debates and information

As a member you can...

Access the Learning & Development centre for your team

Network with investors, collaborators and customers

Be seen as an employer of choice

Raise your company’s profile

Do get in touch to learn more about membership benefits and how to maximise the return on your investment.

Membership Benefits

Benefit Gold Silver Non-member

Listed in online membership directory

Listed in One Nucleus Annual Review

Post news to website and social media

Yes Yes No

Yes Yes No

Yes Yes £75 + VAT*

Advertise jobs on web site Free Free £75 + VAT*

Advertise events on web site Free Free £75 + VAT*

ON Helix In-Person Delegate 2022 £295 + VAT £395 + VAT £495 + VAT

ON Helix Digital Delegate 2022 1 Comp Pass/member Extras £35 + VAT 1 Comp Pass/member Extras £50 + VAT £75 + VAT

Genesis In-Person Delegate 2022 £295 + VAT £395 + VAT £495 + VAT

Genesis Digital Delegate 2022 1 Comp Pass/member Extras £35 + VAT 1 Comp Pass/member Extras £50 + VAT £75 + VAT

BioWednesdays Free Free £50 + VAT

A4 Advert in eNews £500 + VAT £500 + VAT £800 + VAT

Member Savings

Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. One Nucleus negotiates savings and discounts for members by leveraging the critical mass of our membership, providing members with the purchasing power of a large entity. Receive discounted rates on laboratory supplies, services, key industry events and more.

Make Even More Savings with the One Nucleus Group Purchasing Scheme

• Gold members can benefit from 10 Preferred Supplier contracts.

• NEW! Silver members can now access 5 Preferred Supplier contracts.

• NEW! 3 new contracts awarded for our members in 2021.

• 001 - utility savings and green energy contracts

• Circular1 Health - COVID testing

• Research Solutions Inc - scientific literature services.

• Saving members over £4 million per annum on a combined spend of £7 million per annum.

• Member retains full control over their own procurement, which is key to R&D operations.

• Member has direct relationships with the suppliers, including access to services which are customised to their needs.

• Gold Members using Fisher Scientific receive a growth rebate on their annual spending at the end of the year - rebate in 2021 was 5.5%. The overall savings made, easily cover the cost of a Gold Membership.

• All Preferred Suppliers have published sustainability plans and policies to protect customers’ environmental footprint.

Member Savings

Member to Member Marketplace:

• Convenient destination to find an array of discounted products and services.

• 19 Support Suppliers offering discounts to One Nucleus members.

Events:

• A free Digital Delegate Pass for each One Nucleus member company to ON Helix and Genesis. A combined saving of £150 + VAT over non-members.

• Discounted delegate rates at ON Helix and Genesis for in-person or additional digital delegates.

• A range of discounts at international and national industry partnering events and conferences such as BIO-Europe Spring, BioTrinity, AngloNordic Conference, BioIntegrates, BIO Convention, Medi-Integrates, NLSDays and Bio-Europe.

Facilities Management:

• Accessing expertise - Our Chief Technical Specialist, Richard Dickinson, has over 25 years’ experience as a Facilities Manager.

• Provision of project management for office and laboratory fit-outs and can assist with laboratory service contracts, maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting.

• Daily Rates (excluding VAT) – Gold members £700 plus expenses; Silver £850 plus expenses; Non-member £1,000 plus expenses.

• View case studies.

• Contact Richard Dickinson to discuss your needs and secure a quote.

Facilities Management

Facilities management can be a real problem for small technology companies with challenging demands for laboratory, workshop and office space. One Nucleus provides a range of Facilities Management Services to help our member companies to expand or relocate.

We provide project management for office and laboratory fit-outs (no job too small), help with laboratory service contracts, maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting. As with all our services, these are provided at discounted rates to our members.

Our Facilities Management Services and Purchasing Scheme are managed by Richard Dickinson, One Nucleus’ Chief Technical Specialist, who has more than 25 years’ experience in laboratory and facilities management. Richard has extensive local contacts and is also NEBOSH certified in health and safety.

Recent projects and clients include:

• Alchemab Therapeutics Ltd

• Broken String Biosciences Ltd

• Cambridge Epigenetix Ltd

• Charm Therapeutics Ltd

• Clover BioPharmaceuticals UK Ltd

• Healx Ltd

• Nuclera Nucleics Ltd

• Summit Oxford Ltd

• Superdielectrics Ltd

• VaxEquity Ltd

Companies Richard has helped this year have a total of 166,500 sq. ft. of space.

Partner with the world leader in serving science

EAST OF ENGLAND DEAL MAKING ACTIVITY

The East of England is a vibrant hub for biotech and life sciences. Home to more than 200 research institutions, biotech start ups and SMEs, the East of England continues to go from strength to strength. Fundraising has been traditionally in the spotlight; however, the deal making activity and the type of transactions that take place are equally important. Deals are a good indication of the innovation that takes place in this region and its impact.

During the last 2 years (2020 & 2021), 143 companies and research institutions in the East of England have disclosed 251 deals collectively1. Despite a small decline compared to the previous year, the 2021 deal activity in the East of England remained at high levels. 2021 saw 119 disclosed deals, a 10% decline in deal making comparing to the 132 disclosed deals of 2020.

The number of transactions remained relatively stable throughout 2021. Q1, Q2 and Q4 recorded 31 deals each while Q3 witnessed 26 deals. This translates to an average of 30 deals per quarter and is not far from the 2020 average of 33 deals per quarter.

As with 2020, the majority of the 2021 deals comprised Research Collaborations (54.6%), Licensing agreements (15.1%) and Development & Manufacturing agreements (10.9%). However, 2021 saw a clear shift towards Research Collaborations. Research Collaborations increased by 35% year-over-year (YoY) while Licensing and Development & Manufacturing agreements experienced a 48% drop YoY. Company Acquisitions were also noteworthy, almost doubling from 5 (2020) to 9 (2021).

Deal

Research Collaboration 48 65

License 35 18

Development & Manufacturing 25 13

Company Acquisition 5 9

Co-Development 7 5

Distribution Agreement 4 3

Manufacturing & Supply 3 n/a

Asset Purchase 3 n/a

Merger n/a 2

Joint Venture 1 2 Co-promotion n/a 1 Fundraising, Research Collaboration & Option to License 1 1

Research Collaborations

The vast majority of the 2021 Research Collaborations came without a disclosed commercial component – only 11% (7/65) disclosed a license or an option to license at a later stage.

Besides an increase in the total number of Research Collaboration deals, 2021 saw a substantial increase in the number of Research Collaborations that involved preclinical assets (2.3-fold increase) and assets in clinical trials (6-fold increase) compared to 2020.

The clear front runners in terms of therapeutic areas were cancer and infectious diseases. Cancer deals more than doubled comparing YoY (34 vs 13) and accounted for 52% of the Research Collaborations.

On the other hand, Research Collaborations for Infectious Diseases remained relatively stable between the two years (17 vs 14). Unsurprisingly, the Infectious Disease collaborations revolved almost exclusively around COVID-19 (>90% of the Infectious Disease Research Collaborations in both years); a trend that reflects the effect of the pandemic and the urgency for research and innovation. The majority of the Infectious Disease Research Collaborations related to therapeutics – especially in 2021 – and comprised mainly research on New Molecular Entities instead of repurposing compounds.

* Other refers to assets at an undisclosed stage of development, agreements for basic research (sample testing, biomarker research, target validation, etc.), and collaborations around platform technologies (AI applications, screening platforms, etc.).

Licensing Agreements

Licensing deals experienced the biggest drop YoY among the different types of deals (48.6% drop). Licensing deals in 2021 displayed a decrease in both absolute numbers and diversity. 18 deals were struck in 2021, of which 17 referred to drugs and 1 to a companion diagnostic. In comparison, 2020 saw 35 licensing deals; 29 referred to drugs while the remaining included diagnostics, expression platforms, drug delivery technology, cell conversion technology and sequencing technology.

Assets at an earlier stage of development (Discovery & Preclinical) were generally favoured across both years. A good number of licensing deals involved launched products in 2020 (4 deals) however, this trend did not follow up in 2021 (1 launched product deal). Cancer and Infectious Diseases were the prevalent therapeutic areas for Licensing deals as well.

Partner Country of Origin

Companies from the East of England tend to find themselves on the science/technology originator side rather than the commercial partner, which is the case for approx. 58% of the deals in both 2020 and 2021. When looking exclusively at the licensing and asset purchase deals, this percentage increases to 63% and 61% for 2020 and 2021 respectively, supporting the value of the East of England as an innovation hub.

The innovation taking place in this region attracts both foreign and domestic partners. UK-based companies appear to be the main type of partner for 2021, representing 36% of the overall deal activity, a 2% increase from 2020’s 34%. The USA is a close second (31% of 2021 deals; 36% of 2020 deals) and represents the biggest pool for overseas partners. The remaining partners are widespread and stretch from Canada and Europe all the way to Asian markets such as Japan and China.

Deal Financials

Out of the 119 deals for 2021, only 17 had financial details disclosed. These deals span research collaborations, licenses, asset purchases, co-development agreements, fundraising and company acquisitions, and could amount to more than $21 BN (~£15.6 BN) including contingent milestones. The median deal size in 2021 stood at $1.2 BN (£890 M) with a balanced split between upfront and milestone payments. The considerations paid included both cash and equity.

All Deals 2021

Median 1,190.5 300.5 227.5

Average 1,241.5 920.5 733.8

Min 17.0 12.0 8.0

Max 7,200.0 7,200.0 2,600.0

Upper Quartile 1,400.0 1,025.0 1,062.5 Lower Quartile 300.7 18.1 56.0 n 17 14 6

2021 Licensing agreements with financials disclosed had a median deal size of $68.3 M (~£51 M) and were backloaded with most of the payments tied to development and regulatory milestones – milestone payments outweighed upfront payments by almost 4:1.

Company acquisitions had a different deal structure, with most of the value coming as upfront, as expected. Milestones/ Contingent consideration were less frequent and when present represented a fraction of the total deal size (13-24%).

Research Collaborations came with a hefty deal size but they found themselves on the other end of the deal structure spectrum, with almost all of the value tied to development and regulatory milestones. Research Collaborations in 2021 saw

outweigh upfront payments by 14:1.

been even fueled

in

Zone 2 is a new ~240,000 SF three-building development located on a best-in-class science park in Cambridge, Granta Park.

Granta Park is an inspirational 120 acre estate that perfectly captures the essence of Cambridge and the life sciences community with beautiful, green surroundings, creating the ultimate environment for a work-life balance.

BioMed Realty, a Blackstone portfolio company, is a leading provider of real estate solutions to the life sciences and technology industries.

ZONE

GRANTA

Providing Space for the Pioneers of Life Sciences

As a world-leading developer, owner and operator of mission critical real estate solutions for the life sciences and technology industries, we’re proud to have a strong presence in both Cambridge, MA, and Cambridge, UK. In these vibrant ecosystems, the innovators and enterprising companies to whom we provide the necessary space to thrive, are in search of accelerating breakthroughs that seek to solve the biggest healthcare and bioscience challenges of our age. They need the right assortment of equipment, but also curated laboratory and office environments to succeed — and it is these ingredients which we offer to the hundreds of tenant partners across our trans-Atlantic portfolio.

Because innovation happens in proximity, not in isolation, life sciences hubs thrive by having access to a large talent pool, nearby academic and research institutions and close proximity to venture capital and other investors. The UK life sciences ecosystem not only has these key elements, but is also fueled by the growth in tenant demand underpinned by funding into the sector.

Of the 13.7 million square feet of research and workspace BioMed owns and operates in the UK and US, approximately one million square feet is in Cambridge, UK. This space is all fully leased, having recently welcomed two pioneering companies – Altos Labs and Bicycle Therapeutics – to our recently renovated Portway building at Granta Park, one of the largest purpose-built life sciences developments in the Oxford-Cambridge Arc and home to over 30 of the world’s largest life sciences companies and research organizations, including Pfizer, Illumina and Cancer Research UK. This represents a formidable cluster of collaboration and innovation that employs more than 3,700 people.

In addition to the 13.7 million square feet of operational space, BioMed maintains a premier development platform with 3.5 million square feet of Class A properties in active construction. To extend the runway of supply for the burgeoning life science sector globally, we’re also actively looking for ways to continue expanding this pipeline in all our key markets — including the UK — as represented by last year’s announcement that we intend to nearly double the size of our portfolio in Cambridge. Our best-in-class portfolio, market-leading platform and growing pipeline allows us to meet rapidly increasing demand in the UK.

The UK life sciences industry is world-leading and life-saving, as the Oxford University and AstraZeneca COVID-19 vaccine demonstrated. The UK has consistently had strong government funding into the sector, with UK government spending on healthcare and R+D the highest in Europe and second in the world.

But it is not only the convergence of academic ties, government support and private investment that life sciences companies need. The pandemic has shown that some industries can operate successfully with remote workers, but essential lab work for drug discovery cannot be done from home. It requires highly specialized research and workspace. Having the right building in the right location is just as important as having the right talent.

Bill Kane, President - East Coast & UK Markets, BioMed Realty www.biomedrealty.com

Success is our science

The life sciences sector is hugely innovative but also highly complex and regulated. Our renowned multi-disciplinary team of lawyers have deep sector knowledge and can help wherever you need, whether that is to protect your latest idea, to execute complex transactions or deal with compliance issues. We provide the solutions to enable you to seize the opportunities open to you.

To find out more, please contact: James Fry Partner and Head of Life sciences james.fry@mills-reeve.com www.mills-reeve.com

Increasing Sophistication in the Pharma/ Biotech Partnership Model

The last couple of years have seen the life sciences industry propelled into the mainstream news. Advanced technologies like mRNA vaccines and novel antivirals have received unprecedented public attention, and for good reason as the sector provides a powerful toolkit to respond to the global challenge of the COVID-19 pandemic. Investment in the sector has been strong with reports of 2021 surpassing previous records for fundraising for UK life sciences and biotech companies, reaching some £4.5bn. This will support and drive forward continuing innovation

Teamed with exceptional levels of investment, we are also seeing increased activity amongst peer-to-peer dealmakers in the sector. Biotech companies with strong proprietary technologies can offer new routes to tackling unmet need alongside more tried and tested approaches to drug discovery. This dynamic can shift the power balance in favour of the smaller partner, which enable it to retain more control over the applications for its technology.

Important strands for a biotech partner include the following points.

Define carefully the scope and extent of each licence. While licences in the past might have been broadly cast to allow a wide range of activity and target-seeking on the part of the licensee, there is now greater sophistication in the allocation of fields of activity between technology users. In addition to helping the biotech innovator to realise full value for its technology, it also enhances the likelihood that important patient benefits will be realised across a broad range of needs. A licensee will focus R&D effort on its own areas of interest, leaving neighbouring fields to be taken forward by others. Mechanisms to make this work include gatekeeper arrangements that serve both to protect the biotech’s in house programmes and those of all of its licensees.

Identify and retain control of fields for in-house R&D. We are seeing biotech innovators select fields that will be reserved for in-house R&D. While biotech companies may in the past have left drug discovery and development to major players with an international presence and well-resourced development machine, many now see carefully defined projects as a part of their own remit. If progressed effectively, these can offer an important potential source of revenue. The high risk profile of in-house development can be offset by revenue streams from out-licensing in other areas.

Consider per-target pricing models. Biotech companies are increasingly looking at pricing that is based on the number of targets that a partner will select and take forward using the licensed technology. Where a particular target does not progress well, a replacement mechanism is usually appropriate. However, retaining control over the ultimate number of projects helps the biotech provider to realise full value from its technology.

The different shape and character of any particular collaboration will determine the extent to which these considerations apply, but we see these factors coming into play across many types of activity.

James Fry, Mills & Reeve www.mills-reeve.com

It takes a Network…

More than a membership organisation, One Nucleus is a network with many ways in which to interact and draw benefit from it. Think of it as a social group with a nucleus of core elements which would be active in managing the activities and working on maintaining the connections – this would be your devoted One Nucleus team! – the other elements of the group would then interact as much, or as little as they wanted but sharing a common goal. For the social group it could be as simple as having fun, and for a group like One Nucleus it is to leverage collective strength and intelligence to progress their business, career or product development.

As there is no better place than the Annual Review feature to reflect on this network as a whole, here is a representation of the One Nucleus network and importantly, our valuable members.

Introducing One Nucleus membership

There are numerous reasons for becoming a One Nucleus member including profiling opportunities, making new contacts, sharing and learning with peers, or saving money with our purchasing scheme, but there is always one common factor: the contribution to the life science innovation value chain.

This value chain, ranging from public research institutions to large drug developers with all stages of company in between, is fully represented in the One Nucleus membership accounting for 31% of its total. The discovery and development backbone could not deliver on its promise without the increasingly specialised support from technology providers representing another 30% of the network and ranging from niche technical services in data, chemistry or biology to broad spectrum CROs and CDMOs. The rest of the support is a highly specialised group of professional services helping companies operations as well as their strategic development.

Here is a more detailed representation of One Nucleus members with examples. The breadth of expertise and span of company size is a great reflection of the wider One Nucleus community and one of the keys for the network success.

It takes a Network…

Understanding the regional dynamic

The One Nucleus membership ecosystem does not exist in isolation, but sits within the surrounding cluster centred on Cambridge; the two sharing a very symbiotic relationship.

Not all of its geographic neighbours, whether public or private organisations, will be One Nucleus members at any given point. The value of membership being dependent on their status, activity plans or employees’ availability to engage. Importantly, One Nucleus maintains comprehensive connectivity with, and awareness of, the whole ecosystem. Our understanding of the whole, not just our members with our flexible approach to engaging non-members, makes One Nucleus the go-to network for the region.

Breakdown of Therapeutics Biotech in East of England

Laboratory Services

, Restore Harrow Green are

If you’re relocating

handle every aspect of your project. Our advanced knowledge of laboratory operations means we are able to handle:

Samples,

All

Instruments

you can trust

We

IT,

Clean

O

We

In

our

It takes a Network…

This breakdown is a good reflection of the key technology expertise in the East of England region. Not only are most of these companies at the cutting edge of their science topic but they are also active deal makers, as analysed in the article ‘East of England’ deal activity on page 32 of this Review.

In conclusion there are many ways to interact with the One Nucleus community, but it always has to start by acknowledging this community - it encompasses both members and the wider network. The annual review is a good place to start with the following A- Z list of members.

In describing the network, the aim is to illustrate One Nucleus’ role in helping all stakeholders to solve the ‘big challenges’; generating the best biotech innovations, developing the best treatments and being the best life sciences cluster.

International Connections for Local Benefits

With Life sciences being a truly global sector, international connectivity is vital. Set out below are some key international facing activities One Nucleus undertakes.

Leveraging international conferences

Events like BioEurope or BIO are great opportunities for life science companies to make connections and develop their international footprint. Through our collaboration with EBD group and other conference providers, One Nucleus secures significant discounts on registration fees for its members.

Bringing the rest of the world to us

Understanding the life science sector characteristics of other geographical locations is also an important component of international business development. Governments can provide effective overviews and key data but hearing directly from those within an ecosystem often provides more practical insight. We are very privileged at One Nucleus to have a fantastic network of international bioregions, represented below, who are willing to engage in our activities and interact with the One Nucleus network.

Examples of sessions at Genesis 2021 to highlight and connect key international One Nucleus partners included:

Accelerating Market Access for Digital Health Innovation between Québec and UK Learn about the Latest Japanese Startup Ecosystem Hong Kong Biomedical Cluster and Leading IPO Center in Asia

It

a Network…

Looking to 2022, we’ll get back to hosting in-person international delegations so watch this space as your next international partner may come to your doorstep.

Building a consortium to better support our network

The latest addition to our toolbox to support our members, is a consortium involving One Nucleus, BioCat in Barcelona, STUNS in Uppsala, CHealth in Estonia and Eurasante in Lille to support life science companies on their digitalisation journey. Digitalisation is not new, but is revealing some very sector-specific challenges when bringing sophisticated data technologies and skills to highly established and regulated industries.

These challenges are not simply a UK matter and members do not just look domestically. To learn from expertise in other geographies, and develop effective new support offers for our members, One Nucleus has entered a new EU-funded project entitled BRIGHT. Working with Biocat (Barcelona), STUNS (Uppsala), CHealth (Estonia) and Eurasante (Lille), the programme will map and compare the common challenges and develop services to address support gaps whilst developing close connections with these leading European life science and digital hubs. Connections we can share with our members.

This opportunity would never have been available without our involvement in the Council of European BioRegions, a European network of bioclusters. The group enables the development of relationships with key contacts in various parts of Europe. It acts as a forum for exchanging good practice in supporting life science and healthcare companies.

It reinforces our view that it takes a global vision to be a good local supporter! To discuss these international opportunities, please contact Tony: tony@onenucleus.com

Member A-Z Listing

A-Z Listing

001 Limited A4Pbio Abcam plc Abzena (Cambridge) Limited ACellZ Limited Actigen Limited Adaptate Biotherapeutics Limited Adrestia Therapeutics Ltd Advent Life Sciences LLP Agenda Life Sciences Agenus UK Limited Agility Life Sciences Air Liquide UK Ltd Air Products PLC Alchemab Therapeutics Ltd All Med Pro Alloy Therapeutics UK Ltd Alpha MD Limited AlphaSales Limited AltemisLab Limited Amphista Therapeutics Ltd

AMS Advanced Medical Services

AMS Biotechnology (Europe) Limited (AMSBIO)

Antikor Biopharma Apollo Scientific Limited Apollo Therapeutics Limited Apple Tree Life Sciences (UK) Limited Appleyard Lees IP LLP

Aptamer Group plc

Aqdot Ltd Arecor Limited Arise Innovation Centres (part of Anglia Ruskin University (ARU))

ArkVax Limited Artios Pharma Limited Asahi Kasei Pharma Aspire Biosciences Astellas Pharma Europe Ltd Astex Pharmaceuticals Ltd AstraZeneca Astrea Bioseparations Ltd Atelerix Ltd

ATG Scientific Ltd Autolus Limited Avacta Life Sciences Ltd Avantor Inc (VWR)

Aviadobio Limited AZoNetwork UK Ltd

B

Babraham Institute Enterprise Limited Babraham Research Campus Ltd Bactobio BBI Cambridge Ltd Beacon For Rare Diseases Beauchamp Technology BenchSci UK Limited BenevolentAI BicycleTx Limited Bidwells Bio Transcript Partners LLP Biocair - UK Biocrucible Ltd Biofaze Limited Biofidelity Limited BioIVT BioM Biotech Cluster Development GmbH BioMed Realty

A-Z Listing

BioMedica Diagnostics Inc

BioNJ

Bionow BioPartner UK

BioPharmaLogic LLC

Biorbyt Ltd

Biosynergy (Europe) Ltd

Biotechnology Innovation Organization (BIO)

bit bio Ltd

Blue Link Worldwide UK Limited BOC Boehringer Ingelheim Boult Wade Tennant Boyds Bridge Partners Ltd Bristows LLP

Broken String Biosciences Ltd Bruntwood SciTech

Business France - Healthcare/Biotech Team

Cambridge Employment Law LLP

Cambridge Enterprise Limited

Cambridge Innovation Capital (CIC)

Cambridge Network Limited

Cambridge Pharma Limited

Cambridge Rare Disease Network (CRDN)

Cambridge Research Biochemicals

Cambridge Science Park

Cambridgeshire Chambers of Commerce

Camlab Ltd

CAM-SCI

Canadian High Commission Cancer Research UK (CRUK)

Carocell Bio Limited

Catalent Pharma Solutions

Cell Signaling Technology Cellomatics BioSciences Ltd Centre for Process Innovation (CPI) Cerevance Ltd Charles Consultants (Life Sciences) Ltd

Charles River

Charles Stanley & Co. Limited CHARM Therapeutics Limited

Charnwood Campus Management Ltd Chesterford Research Park Chiesi Limited

Child Growth Foundation CIMYM BioSciences Ltd Cinference UG Clinion UK Ltd

Closed Loop Medicine Limited

CMS Cameron McKenna Nabarro Olswang LLPLife Sciences Team

CN Bio Innovations Collaborative Drug Discovery Colorifix Ltd

Complete Business Solutions Group Ltd Congenica Ltd

Constructive Genomics Ltd

Coulter Partners Creasallis Limited

Creative Places LLP Crescendo Biologics Cryoniss Ltd.

Curileum Discovery Ltd CW (Cambridge Wireless Ltd) CY Partners Recruitment Limited Cytocell Limited

A-Z Listing

D Young & Co LLP

Deep Science Ventures Deliver Plus Limited Deloitte Diosynvax Ltd (DIOSVax)

Discovery Park Limited Discuva Ltd DIVERSA Technologies DLRC Ltd DNAe Group Holdings Ltd Domainex Ltd

Dr Clare Sansom Freelance Science Writer

Dr. Reddy’s Laboratories (EU) Ltd Drishti Discoveries Limited DyoDelta Biosciences Ltd

Earlham Institute

Eastern AHSN

EBD Group

Educo Life Sciences Limited EIP

Eli Lilly

Elixa MediScience Ltd

Ellarion Cybernetics Ltd Embassy of Switzerland Emberion Limited EMBL-EBI

Empyrean Therapeutics Ltd Enedra Therapeutics Limited Entact Bio Limited Epidarex Capital Epitopea Ltd

Ergomed PLC Ernst & Young LLP (EY) Essen BioScience Ltd ET-traps Limited Eurofins Genomics UK Ltd Eurofins Selcia Limited Evonetix Evotec UK Ltd ExecMind International Executive Search F.institute - UK Fish & Richardson P.C Fisher Scientific UK FOx Biosystems Limited FOx Biosystems NV Freeline Therapeutics Limited Freeths LLP

F-star Therapeutics Limited Fusion Antibodies PLC Galecto, Inc. (Stevenage) Gallagher Life Sciences Practice (UK)

GCR Camprop Fourteen Limited GENEWIZ UK Ltd Genomics England George James Ltd Goodwin - UK Government of Québec Greenleaf Processing Ltd

A-Z Listing

Haier Biomedical UK Limited Harlow Council HC Pharma Consultancy Limited Health and Safety Works Ltd Health Tech Enterprise Healx Ltd Hide Biotech Limited Highbury Regulatory Science Limited Histocyte Laboratories Ltd Horizon Discovery Ltd Horus Security Consultancy

Howard Group - Howard Ventures Illumina Cambridge Ltd ImaginAb Europe Immodulon Therapeutics Independent - Martino Picardo Independent - Miranda Weston-Smith Infex Therapeutics Limited

Inivata Limited Innomech Ltd Innovate UK Instinctif Partners (Life Sciences) IONTAS Ltd iosBio Ltd IP Pragmatics Limited Isogenica Ltd Isomerase Therapeutics Ltd

J A Kemp LLP

Johnson & Johnson Innovation (JnJ)

Kao Data Kathryn Simpson Consulting Limited Kelyon Kidney Research UK King’s College London (KCL) KISS Communications KPMG LLP (Life Sciences) Labcorp Early Development Laboratories Ltd - Al conbury Ladder Therapeutics Limited Latham & Watkins Leaf Expression Systems LEX Diagnostics Limited LifeArc Lifesci Search Limited LifeSciences British Columbia Lightox Limited LINK-J (Life Science Innovation Network Japan, Inc) London BioScience Innovation Centre (LBIC) London Stansted Cambridge Consortium (LSCC) Lonza Biologics Plc

MMacfarlan Smith (Veranova - Cambridge) Macomics Limited Management Learning & Coaching Limited Mandeville Technology Limited Marks & Clerk Mathys & Squire LLP Maxion Therapeutics Limited MedCity Medical Research Council (MRC)

A-Z Listing

Mercury Bioscience Consultants Ltd Mestag Therapeutics Limited Metrion Biosciences Mewburn Ellis LLP Microbiotica Mills & Reeve LLP Mind Over Cancer MIP Discovery Ltd Mission Therapeutics Limited Mogrify Limited Monument Therapeutics Limited MSD MultiplAI Health Murray International Partners Ltd Mursla Limited MyData-T Ltd Myricx Pharma Ltd

Nanna Therapeutics Ltd NanoSyrinx Limited Nationwide Laboratories Neobe Therapeutics Limited NeoGenomics Laboratories, Inc New England Biolabs (UK) Ltd New Path Molecular Research Limited Newcastle BioSphere Nexus Intelligent Engineering NK:IO LTD North Highland Norwich Research Park Novogene (UK) Company Ltd Novotech Nuclera Nucleics Ltd

Oo2h Ltd Oak Zone Biotech UK Limited OMass Therapeutics OncoLytika Ltd ONO Pharma UK Ltd Onyva the Agency Oppilotech Ltd Optimum Strategic Communications Origin Sciences Limited Osborne Clarke Oyster Venture Partners Limited (OVP) Paramotif Ltd Parkinson’s Concierge Partners& - Life Science Insurance PCML

PPCR Bio Systems Limited Penningtons Manches Cooper LLP PeproTech EC Ltd Pharma International PharmaGuide Ltd PharmaLex UK PharmaMedic Consultancy Limited Pharmaron UK Ltd PharmaVentures Ltd

Phico Therapeutics Ltd PhoreMost Ltd Photography for Healthcare & Biotech PiR International PPMLD Ltd

Precision for Medicine - UK group

Precision Health Technologies Accelerator (PHTA)

A-Z Listing

PrecisionLife Ltd ProductLife Ltd ProPharma Partners Limited Protogenia Consulting Ltd

QRC Consultants Ltd Quadram Institute Bioscience Queen Mary BioEnterprises Ltd Queen Mary Innovation Ltd Queen Mary University of London (Business Devel opment)

Quotient Sciences Ltd Rare Biotech Ltd Reading Scientific Services Ltd (RSSL)

Reddie & Grose LLP Reed Scientific Release Life Sciences and Diagnostics Ltd (RLS) Research Solutions Inc - UK Restore Harrow Green Roslin Cell Therapies Limited RSM Sagittarius IP Salve Therapeutics Inc Sania Rx Limited Scendea Ltd SCi Partners LLP sciTribe Consulting Limited Semarion Limited Sense Biodetection Ltd

Shionogi B.V. Silicon Valley Bank Simcere UK Limited Singular Talent Limited SIP Cambridge Sky Bio Ltd Somaserve Ltd Sookio Limited Sosei Heptares - Cambridge Source Bioscience - Genomics Unit Spirea Ltd. St John’s Innovation Centre Ltd Standigm UK Co Ltd STARLAB (UK) Ltd Start Codon Ltd STEMCELL Technologies UK Ltd Stevenage Bioscience Catalyst Storm Therapeutics Ltd Superdielectrics Ltd

Suzanne Meenan Consulting Swift Molecular Diagnostics Limited Sygnature Discovery Ltd Talisman Therapeutics Ltd Talwarbio Limited

Taylor Vinters

Taylor Wessing

The Brain Tumour Charity

The Cambridge Crystallographic Data Centre (CCDC)

The Communications Strategy Group Inc.

The Institute of Cancer Research

The Royal Veterinary College (RVC) Theradex (Europe) Ltd

A-Z Listing

Thermo Fisher Scientific tranScrip Transine Therapeutics Trident BioPharm Solutions Limited TTP plc Tuspark Cambridge

WalkBek Consulting Limited Waracle - Digital Health

UK Health Security Agency (UKHSA)

UKSPA United Airlines

University College London - SysMIC University College London (UCL) University of Cambridge University of Essex - Research and Enterprise Office University of Leicester- Enterprise & Business De velopment Office

University of Nottingham - Corporate Partnerships Vaccitech (UK) Ltd ValiRx Plc

Varsity Pharmaceuticals Limited VaxEquity Ltd. VectorBuilder Inc Venner Shipley LLP Verinnogen Vernalis Ltd VirdisGroup Ltd Vitrolife

Voisin Consulting Life Sciences

We are Pioneer Group - Life Sciences Team Wellcome Genome Campus Wellcome Sanger Institute Withers & Rogers LLP Wren Therapeutics Limited WuXi AppTec UK Ltd Xampla Limited

you